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ABSTRACT 
In the search for specific genes regulated by DNA methylation in RA, we investigated the 
expression of CXCL12 in SF and the methylation status of its promoter and determined its 
contribution to the expression of matrix metalloproteinases (MMPs). 
DNA was isolated from SF and methylation was analysed by bisulphite sequencing and 
McrBC assay. CXCL12 protein was quantified by ELISA before and after treatment with 5-
azacytidine. RASF were transfected with CXCR7-siRNA and stimulated with CXCL12. 
Expression of MMPs was analysed by Real-Time PCR.  
Basal expression of CXCL12 was higher in RASF than osteoarthritis (OA) SF. 5-azacytidine 
demethylation increased the expression of CXCL12 and reduced the methylation of CpG 
nucleotides. A lower percentage of CpG methylation was found in the CXCL12 promoter of 
RASF compared to OASF. Overall, we observed a significant correlation in the mRNA 
expression and the CXCL12 promoter DNA methylation. Stimulation of RASF with CXCL12 
increased the expression of MMPs. CXCR7 but not CXCR4 was expressed and functional in 
SF. 
We show here that RASF produce more CXCL12 than OASF due to promoter methylation 
changes and that stimulation with CXCL12 activates MMPs via CXCR7 in SF. Thereby we 
describe an endogenously activated pathway in RASF which promotes joint destruction.  
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1. INTRODUCTION 
A variety of studies describe an activated phenotype of synovial fibroblasts (SF) in 
rheumatoid arthritis (RA) which is characterized by a changed morphology, deranged 
apoptotic behavior, and increased invasive properties 1. Recently, we found that epigenetic 
changes might contribute to these phenotypic changes in RASF. We could show that DNA of 
RASF is globally hypomethylated when compared to osteoarthritis (OA) SF or normal SF and 
that less DNA methyltransferase DNMT1, the enzyme responsible for DNA de novo 
methylation is present in RASF 2. DNA methylation is well known to regulate gene 
expression. Transcriptional regulation by DNA methylation occurs in CpG rich regions of 
gene promoters, so called CpG islands. Methyl CpG binding proteins bind to methylated CpG 
islands and together with chromatin remodeling enzymes cause gene silencing 3. In the 
normal genome, DNA methylation regulates gene expression to form tissue specific 
expression  patterns 4. Aberrant DNA methylation was found in various pathologies including 
cancer and autoimmune diseases 5, 6. 
CXCL12, also known as stromal-derived factor-1 (SDF-1) is a key player in the trafficking of 
lympho- and hematopoietic progenitor cells and in the early development and regeneration of 
tissues 7. Moreover, the secretion of CXCL12 is increased after tissue damage by hypoxia, 
toxins or irradiation, leading to the immigration of progenitor cells expressing the CXCL12 
receptor CXCR4 8. A second receptor for CXCL12, CXCR7 has only most recently been 
identified and has been implicated in tumor growth and metastasis 9-11. Elevated levels of 
CXCL12 were found in patients with multiple sclerosis, inflammatory myopathies, 
spondyloarthropathies and RA 12-17. Levels of CXCL12 in the synovial fluid of RA patients 
are around 10 times higher than in healthy joints and reach a mean of 750 ng/ml 16. It is 
understood that CXCL12 drives chronic inflammation by attraction of monocytes and 
lymphocytes into the joint and by stimulation of synovial fibroblasts to produce pro-
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inflammatory cytokines 17-20. Previous studies also showed that cultured RASF produce more 
CXCL12 than normal or OA synovial fibroblasts 16, 21. 
Based on these results, we analyzed in the current work whether expression of CXCL12 in 
RASF is modified by changes in DNA methylation. Furthermore, to elucidate CXCL12 
signaling pathways we looked at the expression of CXCR7 in synovial fibroblasts and tested 
whether CXCR7 mediates the production of matrix-metalloproteinases (MMPs) after 
CXCL12 stimulation in RASF. 
 
2. MATERIAL AND METHODS 
2.1 Patients and tissue preparation: Synovial tissues were obtained from trauma patients 
(normal synovial fibroblasts, NSF, n=2), RA n=14 and OA n=11 patients undergoing joint 
replacement surgery at the Schulthess Clinic Zurich after written consent (Table 1).  All RA 
patients fulfilled the American College of Rheumatology criteria for the classification of RA 
22. Normal lung fibroblasts were isolated from open lung biopsies of patients suspected with 
cancer but with a negative diagnosis. Synovial fibroblasts and normal lung fibroblasts were 
isolated and cultured as described previously 23. 
2.2 Bisulphite sequencing: Genomic DNA was prepared from synovial fibroblasts using the 
QiAmp DNA blood Mini kit (Qiagen, Hombrechtikon, Switzerland). The DNA (1µg) was 
bisulphite modified using the EpiTect bisulphite kit (Qiagen). Two rounds hemi-nested PCR 
amplification of bisulphite modified DNA (2 µl) was performed using the AmpliTaq Gold 
polymerase (Applied Biosystems, Rotkreuz, Switzerland). The PCR cell cycle program was 
95°C 4 min ; 95°C 30s, 52°C 90 sec, 72°C 2 min x 5 ; 95°C 30sec, 52°C 90sec, 72°C 90 sec x 
25 ; 72°C 4 min. Primers were designed for two regions of the CXCL12 CpG island promoter. 
The forward 5-GTT TGT GAT TAG TTT ATT TTA TTA-3, reverse 5-CTA AAT AAA 
AAC CAA TAA AAA AC-3 and hemi-reverse 5-AAA AAA TCC TAC TTT CTA TAC-3 
bisulphite sequencing primers amplified the region -741bp to -477bp  and the forward 5-GTT 
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TTT TAT TGG TTT TTA TTT AGT TTT-3, reverse 5- TAC CTC CAC CCC CAC TAT AT-3 
and hemi reverse 5- GAG TTT GAG AAG GTT AAA GGT-3 bisulphite sequencing primers 
amplified the region -244bp to +272bp. The computer software MethPrimer predicted CpG 
islands with the following criteria: island size >100, GC content > 50 % and Obs/Exp >0.6 
and designed bisulphite primers for DNA methylation analysis 24. The PCR purified 
fragments were cloned using the Qiagen PCR cloning handbook according to manufacturer 
instructions (Qiagen). Positive clones were sequenced (Microsynth, Balgach, Switzerland). 
The data was analysed using the BiQ analyzer software 25. 
2.3  McrBC digestion and quantitative Real-time PCR:  The CXCL12 promoter DNA 
methylation was determined by methylation-sensitive McrBC-PCR assay. Genomic DNA 
(1μg) was sonicated using the Diagenode bioruptor (10 min, 15 sec on and 15sec off). The 
sonicated DNA was digested with 10 units of McrBC or mock undigested in a 50μl reaction 
mixture containing 1x NEB2 buffer, 10mM GTP and 0.1mg/ml BSA. The restriction 
digestion reaction was incubated at 37 oC overnight and then the reaction was deactivated 
with heating at 65 oC for 20 min. The McrBC treated DNA and mock samples were purified 
using Qiagen PCR purification protocol kit. Quantitative SYBR green PCR using the 
CXCL12 promoter (-741 to -477) primers: Forward CAC CAT TGA GAG GTC GGA AG, 
Reverse AAT GAG ACC CGT CTT TGC AG, was carried out with the McrBC digested and 
mock samples. McrBC cleaves methylated DNA strands and inhibits PCR amplification. In 
contrast, unmethylated DNA prevents McrBC cleavage and can be measured by quantitative 
PCR. Mock undigested DNA is considered as total amount of DNA used in the reaction. 
Methylated DNA will have decreased Ct values after McrBC digestion. The Real-time PCR 
results were normalized with the mock treated sample DNA (deltaCt) and presented as fold 
induction of PCR recovery after digestion with McrBC. 
2.4 Stimulations: RASF and OASF were seeded at low density 24h before treatment. RASF 
were stimulated with 100 ng/ml recombinant CXCL12 (Peprotech, London, UK). OASF were 
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treated with 0.5 μM or 1 μM 5-azacytidine (Sigma) for 6 days. The cell culture medium was 
changed every 24h and replaced with new 5-azaC.  
2.5 Transfection of CXCR7 small interfering RNA (siRNA): siRNA for CXCR7 and 
double stranded siRNA without homology to mammalian genes (negative control) (both from 
Qiagen) were used for silencing experiments. Also, transfection without siRNA (mock) was 
performed to determine whether the experimental set-up causes unspecific effects. The 
transfections were done by electroporation (Nucleofector, Lonza, Cologne, Germany) using 
transfection reagents for primary mammalian fibroblasts (Basic Nucleofector® Kit; Lonza) at 
a concentration of 0.9 µg siRNA/5x105 cells. Transfected RASF were cultured for 48h before 
efficiency of knock-down was measured by Real-time PCR, FACS and Western blot or before 
stimulations were begun. 
2.6 RNA isolation and quantitative Real-time PCR: Total RNA was isolated using the 
RNeasy Miniprep kit (Qiagen) including DNase treatment. RNA was reverse transcribed 
using random hexamers and multiscribe reverse transcriptase (both Applied Biosystems, 
Rotkreuz, Switzerland). Samples without addition of reverse transcriptase served as negative 
control (non RT). Relative quantification of mRNA levels by TaqMan®/SYBRGreen® Real-
time PCR was done using eukaryotic 18S ribosomal RNA as endogenous control (Applied 
Biosystems). The differences of the comparative threshold cycles (Ct) of sample and 18S 
cDNA were calculated (dCt). Relative expression levels were calculated following the 
formula ddCt = dCt (sample stimulated) - dCt (sample unstimulated). Relative expression was 
calculated using the expression 2-ddCt. The sequence of the primers used for measuring MMP-
1, MMP-2, MMP-3, MMP-9, MMP-13, MMP-14, TIMP-1, TIMP-2, TIMP-3 were previously 
described 26. 
2.7 PCR: mRNA was reverse transcribed using oligo dT and Moloney Murine Leukemia 
Virus reverse transcriptase (both Applied Biosystems, Rotkreuz, Switzerland). PCR was 
performed on a C1000™ Thermal Cycler (Bio-Rad laboratories, Hercules, CA) with the 
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following primer pairs and protocols designed to detect the 4 different CXCR4 mRNAs as 
published on the National Center for Biotechnology Information AceView database. CXCR4 
transcript 1: forward primer GGAAAAGATGGGGAGGAGAG, reverse primer 
CACTTCCAATTCAGCAAGCA; CXCR4 transcript 2: forward primer 
CAGCAGGTAGCAAAGTGACG, reverse primer GTAGATGGTGGGCAGGAAGA; 
CXCR4 transcript 3: forward primer AAGGGTCACCGAAAGGAGTT, reverse primer 
GAAGAGACCGGTGGTCTGAG; CXCR4 transcript 4: forward primer 
GTTAAGCGCCTGGTGACTGT, reverse primer GGTAACCCATGACCAGGATG. 94°C 
5min, 40 cycles with 94°C 30s, 58°C 30s, 72°C 30s and a final elongation of 5min with 72°C. 
β-microglobulin: forward primer AAGATTCAGGTTTACTCACGTC, reverse primer 
TGATGCTGCTTACATGTCTCG. 94°C 5min, 35 cycles with 94°C 30s, 55°C 30s, 72°C 30s, 
final elongation 72°C 5min. Reaction products were separated on a 1.5% agarose gel and 
signals were visualized using ethidium bromide.  
2.8 Western blot analysis: Whole cell lysates were prepared by lysing cells in 2x Laemmli 
buffer. Proteins were separated on a 10% SDS-polyacrylamide gel and transferred to Protran 
nitrocellulose membranes (Schleicher & Schüll, Dassel, Germany). Membranes were blocked 
for 1h at room temperature in 5% nonfat dry milk with 0.05% Tween 20 in TBS and were 
incubated overnight with polyclonal rabbit anti-human CXCR7 (2.8 µg/ml; Abcam, 
Cambridge, UK). To ensure specificity of the CXCR7 antibodies, blots were incubated with 
CXCR7 antibodies which were pre-incubated for 1h at 37°C with or without 10 µg/ml of a 
synthetic CXCR7 peptide (10 µg/ml; Abcam). Afterwards, membranes were incubated with 
HRP-conjugated secondary antibodies (Jackson Immunoresearch, Suffolk, UK). Bound 
antibodies were visualized using enhanced chemiluminescence (Amersham Bioscience, 
Otelfingen, Switzerland). Equal protein loading was confirmed using mouse anti-human -
tubulin antibodies or Ponceau solution (Sigma-Aldrich, Basel, Switzerland).  
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2.9 Flow Cytometry: RASF were detached from the culture flask with accutase (PAA 
Laboratories, Linz, Austria), washed with PBS/1%FCS and incubated with 20 µg/ml of rabbit 
anti-human CXCR7 (Abcam, Cambrige, UK) or of rabbit IgG for 45 minutes at 4°C. Cells 
were washed with PBS/1%FCS and subsequently incubated with FITC-labeled goat anti-
rabbit IgG for 45 minutes at 4°C. Washing steps were repeated twice before analysis of the 
cells in the flow cytometer (FACSCalibur). Data were processed using CellQuest software 
(BD Biosciences, San Diego, CA). 
2.10 ELISA: Synovial fibroblasts were seeded at 1 x 105/ml DMEM and CXCL12 was 
measured after 24h (Figure 1B) or at 2 x 105/ml DMEM and CXCL12 was measured after 24h 
and 96h (Figure 5C) in the supernatants with the DuoSet® ELISA development system (R&D 
Systems, Abingdon, UK) according to the manufacturer’s instructions. 
2.11 CXCL12 blockade: RASFs (2 x 105) were incubated with 1 μg/ml neutralizing anti-
human CXCL12 antibodies (R&D Systems) or IgG control. Fresh antibodies or control was 
added after 48h.Cells were lysed after 24h or 96h. 
2.12 Statistical analysis: All data are expressed as mean ±SEM. Statistical analysis was 
performed using GraphPad Prism software, version 4.03 (GraphPad System, San Diego, CA). 
For analysis between different groups, the Mann-Whitney U, for paired analysis Wilcoxon 
signed rank test was used. P values less than 0.05 were considered significant. 
 
3. RESULTS  
3.1 RASF upregulate CXCL12 mRNA and protein expression. 
To analyse the basal expression of CXCL12 expression in RASF and in OASF, we measured 
CXCL12 mRNA and protein levels in cell culture supernatants after 24h. RASF express 
significantly more CXCL12 mRNA than OASF and NSF (RASF 6.9±0.3 dCt, n=11; OASF 
8.3±0.5 dCt, n=8; NSF 7.5 dCt, n=1; p<0.028) (Fig 1A). Furthermore, we observed that the 
mRNA expression of CXCL12 was positively correlated with the C-reactive protein, a marker 
 8
of inflammation marker in these patients (r =-0.64, p<0.01). RASF produced with 85±12 
pg/ml also significantly more CXCL12 protein than OASF with 52 ±10 pg/ml (Fig.1B).  
 
3.2 DNA methylation regulates the promoter of CXCL12 
To investigate whether changes in DNA methylation might influence expression of CXCL12 
in RASF, we first tested whether the CXCL12 promoter can be regulated by DNA 
methylation. Computational analysis predicted that there are CpG islands upstream of the 
transcription initiation site of the CXCL12 promoter (Fig. 2A). We further analysed the 
region that is 100 bp upstream of exon 1 (-741bp to -477bp) and the region that spans exon 1 
(-244bp to +272bp) by bisulphite sequencing. Our findings showed that NSF have a high 
percentage of methylated CpG nucleotides in the promoter upstream region from -741bp to -
477bp, while in the region -244 to +272, that spans the transcriptional initiation site and exon 
1, all the CpG nucleotides were unmethylated (Fig. 2B). To see whether demethylation of the 
heavily methylated CpG rich region would influence CXCL12 expression, we treated OASF 
with different doses of the demethylating drug 5-azaC and found dose dependent upregulation 
of CXCL12 protein secretion (Fig. 2C). Furthermore, bisulphite sequencing analysis showed 
demethylation of the CXCL12 promoter (-741bp to -477bp) with 1 μM 5-azaC (Fig. 2D). In 
addition, the mRNA expression of CXCL12 correlated with the methylation levels of the 
CXCL12 promoter (r =0.60, p<0.04) as show my McrBC digestion assay (Fig. 2E).Taken 
together, the results of figure 2 indicate that expression of CXCL12 is regulated by 
methylation of its promoter, and accordingly can be increased by demethylation.  
 
3.3 Demethylation of CXCL12 promoter upregulates CXCL12 mRNA expression. 
To investigate whether the methylation status of the CXCL12 promoter is altered in 
fibroblasts of RA patients, we compared the percentage of CpG methylation between RASF 
NSF, OASF and normal lung fibroblasts (Fig. 3A, B). First, a group of 4 pooled RASF 
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patients and a group of 3 pooled OASF patients were compared. The analyzed promoter 
region of CXCL12 had significantly less CpGs methylated in the RASF group than in the 
OASF group (RASF 21% ± 7.2 versus OASF 42% ±7.8). We then analysed whether the 
results from the pooled groups would be reflected in individual patient’s analysis. CXCL12 
promoter had similar changes as seen in the pooled samples (RASF 1-2 27% ± 4.8 versus 
OASF 1-2 46% ± 5.6 ). The CXCL12 promoter in NSF cell cultures was strongly methylated 
(NSF1 54% and NSF2 60%). As expected, the CXCL12 promoter in lung fibroblasts was 
similarly strongly methylated as in NSF or OASF. The above results suggest that normally the 
expression of CXCL12 is repressed by methylation in fibroblasts, but that an epigenetic defect 
in synovial fibroblasts of RA patients causes an intrinsically increased expression of 
CXCL12. 
 
3.4 Overexpression of CXCL12 induces functional changes in RASF 
Stimulation of synovial fibroblasts, chondrocytes and osteoclasts with CXCL12 in vitro was 
previously found to induce the expression of matrix degrading enzymes 16, 27, 28. Since DNA 
methylation induces CXCL12 overexpression, we measured mRNA expression of the 
collagenases MMP-1 and MMP-13, the gelatinases MMP-2 and MMP-9, stromelysin (MMP-
3), and the matrix-bound MMP-14 after stimulation with CXCL12 for 24h in RASF. In 
addition, we looked at the mRNA expression of the tissue inhibitors of matrix 
metalloproteinases (TIMPs) -1, -2, and -3. . CXCL12 levels in joints of RA patients have been 
measured to be on average 375 and 750 ng/ml respectively16, 29. We stimulated RASFs in 
vitro with 100 ng/ml. Stimulation with CXCL12 selectively and significantly increased the 
expression of MMP-1 by 6 ±3 fold, of MMP-3 by 2 ±0.2 fold and of MMP-13 by 4 ±1 fold 
(Fig.4A). In contrast, CXCL12 neither influenced the expression of MMP-2, MMP-9, or 
MMP-14, nor did it change the expression levels of TIMPs. 
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 To see whether endogenous production of CXCL12 by RASFs in culture would be enough to 
stimulate the expression of MMPs, we increased the concentration of CXCL12 in the cell 
culture supernatants by increasing the ratio between seeded cells and medium and by 
prolonging incubation times and added an CXCL12 neutralizing antibody or IgG control (Fig. 
4B). Expression of MMP-1 was decreased 26% after 24h, and 42% after 96h incubation by 
CXCL12 blockade compared to IgG control. 
We then addressed the question whether CXCL12 signals via CXCR4 or the newly found 
CXCL12 receptor CXCR7 in synovial fibroblasts. Transcription of the CXCR4 gene produces 
4 different mRNAs which putatively encode 4 different isoforms of the protein. We analyzed 
the expression of these 4 transcripts in PBMCs, synovial fibroblasts, synovial tissues and 
HeLa cells. None of the tested synovial fibroblasts expressed any transcripts for CXCR4. In 
PBMCs all four transcripts were amplified, whereas HeLa cells expressed transcript 1, 2 and 
4. In RA synovial tissues transcripts 1 and 2 were detectable, probably due to the infiltration 
of lymphocytes, since in OA synovial tissues none of the transcripts was found (Fig.4C). In 
contrast to CXCR4, CXCR7 protein was constitutively expressed in synovial fibroblasts 
(Fig.4D). 
We then silenced the expression of CXCR7 with siRNA (Fig.5A) and examined whether this 
would influence the induction of MMPs in RASF after stimulation with CXCL12 . After 
transfection of siRNA targeting CXCR7, no increase in the mRNA expression of MMP-1, 
MMP-3 and MMP-13 was seen anymore after stimulation with CXCL12 (Fig.5B). From these 
experiments we conclude that CXCR7 is functionally important in synovial fibroblasts and its 
activation by CXCL12 leads to expression of MMP-1, MMP-3 and MMP-13. 
 
4. DISCUSSION 
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In the current paper we show that the high expression of CXCL12 in RASF is due to an 
epigenetic alteration and that high amount of CXCL12, as found in the joints of RA patients 
lead to increased expression of MMPs and to joint destruction. 
 In cancer, both DNA hypomethylation and hypermethylation have been shown to occur 30, 31. 
The promoters of p16 or the DNA repair genes MLH1 and BRCA1 for instance have been 
shown to be silenced by increased DNA methylation in cancer cells 32. Global 
hypomethylation was correlated with demethylation of repetitive sequences e.g. Sata, D4Z4, 
NBL2 and transposable elements e.g. LINE-1 33, 34. We and others have reported global 
hypomethylation of synovial fibroblasts in RA and CD4 T cells in SLE 2, 35. We also showed 
that this global hypomethylation affects the promoter of LINE-1 transposable element in 
RASF and that continuous treatment of NSF with 5-azaC induced changes in gene expression 
that resemble the activated status of RASF such as increased production of MMP-14, CD29 
and cathepsins 2. Also in SLE, hypomethylation of specific gene promoters have been shown 
to contribute to the pathogenesis of the disease 35. Similar to the approach of our current study 
it was shown that normal T cells treated with 5-azaC upregulated LFA1, CD70 and perforin 
and that the CpG islands in the promoters of these genes were hypomethylated in T cells of 
SLE patients 36-38. DNA methylation of promoter sequences can change the binding of 
transcription factors. Transcriptional regulation studies of the CXCL12 promoter revealed the 
presence of E-box consensus sequences which are binding sites for multiple transcription 
factors such as bHLH, NFAT, SP1 and HIF1α. 39-41. The low methylation levels observed in 
the CXCL12 promoter in RASF could change the binding of these transcription factors and 
thereby increase gene expression. In healthy fibroblasts, the CXCL12 promoter was strongly 
methylated in our study. In cancers, it has been shown that DNA hypermethylation of the 
CXCL12 promoter in colon carcinomas, mammary carcinomas and the MCF7 breast cancer 
cell line inhibits tumor metastasis.  
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In the current study basal levels of CXCL12 were higher in RASF compared to OASF. Even 
though these changes were not dramatic, we believe that they are of clinical significance since 
CXCL12 expression positively correlated with levels of CRP. CXCL12 is expressed at high 
levels in RA, and it has been implicated in a number of pathogenic events such as recruitment 
and persistence of inflammatory cells in the synovium, as well as production of cytokines and 
matrix degrading enzymes 16, 17, 20, 28, 42. The role of CXCL12 in cartilage destruction was 
further supported by in vivo experiments which showed that CXCL12 antagonists inhibit 
fibroblast-induced cell infiltration in immunodeficient mice 43. CXCL12 can signal via 
CXCR4 and CXCR7. Expression of CXCR4 has been detected in synovium of healthy 
individuals as well as in OA and RA patients 20, 44. Controversial data is published regarding 
the expression of CXCR4 in synovial fibroblasts. Whereas Garcia-Vicuna et al detected 
CXCR4 in synovial fibroblasts, Kanbe et al did not 16, 28. We also could not detect mRNA for 
CXCR4 in synovial fibroblasts of RA or OA patients. Since, pancreatic cancer cells do not 
express CXCR4 due to promoter hypermethylation, CXCR4 silencing could also occur by 
DNA methylation in synovial fibroblasts. CXCR7, previously named RDC1 was first 
classified as an orphan receptor since no ligand could be found 45. Recent publications have 
then related this receptor to cell recruitment, migration and proliferation after binding of 
CXCL12 in various cell types 9, 46, 47. In the present study, we show that functional CXCR7 is 
also expressed in synovial fibroblasts and that it plays a role in the induction of MMP 
production via CXCL12. Based on our data we hypothesize that while CXCR4 might be 
responsible for CXCL12 mediated cell trafficking into RA joints, CXCR7 mediates CXCL12 
signaling in resident synovial fibroblasts. The exact mechanism of signaling after binding of 
CXCL12 to CXCR7 is not clear yet 9, 46.  Recent studies found an association between 
CXCR7 and the adaptor protein β-arrestin2 48-50. Interactions of arrestins with different 
receptors have been shown to facilitate activation of the MAPK cascade, a signaling pathway 
which is known to regulate also MMPs 51.  
 13
High production of MMPs by RASFs has been identified as major mechanism of joint 
destruction in RA 52. In particular, MMP-1 and MMP-13 were reported to play a crucial role 
in the invasive properties of RASF as shown in the SCID mouse co-implantation model 53, 54. 
Expression of MMPs is regulated by multiple pathways. DNA hypomethylation modulates 
expression of different MMPs in cancer cells. In OA chondrocytes the adipocytokine leptin 
has not only been found to be up-regulated by promoter DNA hypomethylation but also to 
stimulate expression of MMP-13 55. Also, a variety of cytokines and chemokines stimulate the 
expression of MMPs 56, 57. The chemokine CXCL12 was reported to induce the expression of 
MMP-3 in chondrocytes and of MMP-9 in osteoclasts 16, 27. Furthermore, increased gelatinase 
and collagenase activity was described after CXCL12 stimulation in synovial fibroblasts 28. 
Our present data suggest that the increased collagenase activity after CXCL12 stimulation 
stems from increased transcription of MMP-1 and MMP-13. On the other hand, CXCL12 
stimulation neither changed the quantity of MMP-2 nor of MMP-9 transcripts, pointing to 
indirect regulation of gelatinase activity by CXCL12. Since MMP-3 was described to 
contribute to the activation of pro-MMP-9 and we found that MMP-3 is more abundant in 
CXCL12 stimulated cells, it is probable that CXCL12 increases gelatinase activity via 
upregulation of MMP-3 58, 59. Based on the differential induction of specific MMPs after 
stimulation with CXCL12 it can be concluded that CXCL12 does not induce MMPs via the 
Activator Protein-1 (AP-1), since all of the measured MMPs contain an AP-1 site in their 
promoter regions. Differences among the MMP promoters have been described and include 
not only binding sites for different transcription factors but also variability in the number and 
arrangement of binding sites, which strongly increases the complexity of MMP regulation 60. 
In summary, our data show that basal expression of the chemokine CXCL12 is increased in 
RASF due to a defect in gene regulation by DNA methylation. In RA joints, accumulated 
CXCL12 produced by RASF might lead to increased expression of MMPs which mediate 
joint destruction. In addition to the previously reported global hypomethylation, we identified 
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CpG island specific hypomethylation of CXCL12 which is involved in the intrinsic activation 
of RASF and thereby in the perpetuation of RA.  
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FIGURE LEGENDS  
Figure 1. RASF express more CXCL12 mRNA and secrete more protein than OASF. A) 
RASF (n=11, ■) expressed significantly more CXCL12 mRNA than OASF (n=8, ●) and NSF 
(n=1, ●).  The mRNA expression of CXCL12 correlated with the patients CRP levels. B) 
ELISA was used to analyse the amount of CXCL12 release in RASF (n=9) and OASF (n=7) 
cell culture supernatants. RASF released significantly more CXCL12 than OASF. * p<0.05 
 
Figure 2. Expression of CXCL12 is regulated by DNA methylation. 
A) Computational analysis of the CXCL12 promoter region. (blue coloured regions: CpG 
islands) The percentage of C and G nucleotides (CG %) are shown 2000 basepairs upstream 
of the transcription initiation site (arrow) and exon 1. Bisulphite sequencing primers were 
designed to analyse region -741bp to -477bp and -244bp to +272bp of the CXCL12 promoter. 
B) Methylated CpG dinucleotides were found in the region -741bp to -477 of NSF (n=1). 
Each circle represents a methylated (black) or unmethylated (white) CpG dinucleotide. Every 
row represents a different clone.  C) After treatment of OASF with 0 , 0.5 and 1 μM 5-azaC 
for 6 days, amounts of CXCL12 were determined by ELISA (n=4). 5-azaC treatment induced 
dose dependent release of CXCL12 (* p < 0.05).  D) 5-azaC demethylates the analysed 
promoter region as shown by bisulphite sequencing (n=1 OASF, 6 clones were sequenced). E) 
McrBC digestion and CXCL12 promoter (-741bp to -477bp) quantitative PCR of RASF 
(n=11) genomic DNA. Negative correlation between CXCL12 mRNA expression and 
CXCL12 promoter DNA methylation was shown in RASF. 
 
Figure 3. RASF have low levels of CXCL12 promoter DNA methylation.  
A) Bisulphite sequencing of CXCL12 promoter region (-741 to -477) in RASF, OASF, NSF 
and lung fibroblasts. Nine to ten clones were sequenced from two independent RASF and 
OASF patients or from a pooled group of four RASF and three OASF patients. In addition, 
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three to six clones were sequenced from two NSF and one normal lung fibroblast culture. B) 
Summary of the data as percentage of CpG methylation between pooled fibroblasts cell types 
shows that RASF have significantly lower percentage of DNA methylation than OASF. C) 
Summary of the data as percentage of CpG methylation between individual fibroblasts cell 
types shows that RASF have significantly lower percentage of DNA methylation than OASF. 
The methylation percentage was calculated in B and C separately for each clone and the 
average of total number of clones was plotted in the histogram graph. * p < 0.005.   
 
Figure 4.  Overexpression of CXCL12 induces MMPs expression . A) Expression of 
MMP-1, MMP-3 and MMP-13 transcripts are significantly increased after stimulation of 
RASF with CXCL12 (n = 6). Data are presented as x fold change after stimulation relative to 
unstimulated cells. B) Time dependent release of CXCL12 protein in cell culture supernatants 
and inhibition of MMP1 expression using a CXCL12 blocking antibodies (n=3) C) 
Expression of the four known CXCR4 mRNA transcripts 1-4 by conventional RT-PCR. D) 
Western blot showing the expression of CXCR7 protein in HeLa cells and RASF obtained 
from 4 different patients; patient’s samples were loaded twice on a 10% gel and the 
membrane was cut. The left side was incubated with anti-CXCR7 antibodies, the right side 
with anti-CXCR7 antibodies pre-incubated with CXCR7 synthetic peptide; α-tubulin (tub) 
served as a loading control.  
 
Figure 5. CXCR7 is functional in SF. A) Expression of CXCR7 after silencing was 
measured on mRNA level (left panel) and on protein level (right panels). Western blot and 
FACS analysis confirmed silencing of CXCR7 after transfection with siRNA when compared 
to cells transfected with control siRNA. Grey filled line: rabbit IgG; black filled line: CXCR7 
siRNA transfected RASF; black open line: scrambled control siRNA transfected RASF. B) 
MMP-1, MMP-3 and MMP-13 levels in control transfected RASF (sc) and CXCR7 silenced 
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RASF (siCXCR7) with and without CXCL12 stimulation (n = 7). All values are the mean and 
SEM. 
 
 
 
 
Table 1.  Characteristics of the study patients  
 Diagnosis Patient 
 Number 
 
Age  
(years) 
Gender  Disease 
duration 
(years) 
NSAIDs DMARDs RF pos        
(>20 I.U.) 
RA 1 55 f 18 + steroids + 
2 64 f 9 - 
MTX 
hydroxychloroquine 
steroids + 
3 70 m 4 + steroids + 
 4 65 f 15 - MTX + 
 5 52 f 19 - Actemra,MTX + 
 6 69 f 28 - Humira + 
 7 45 f 17 - Salazopyrin,Arava + 
 8 65 m 15 - MTX + 
 9 52 f 21 - Arava NA 
 10 66 f 46 - MTX + 
 11 67 f 37 - Mabthera + 
 12 66 f 16 - Arava, Prednison + 
 13 73 f 7 - Prednison + 
 14 79 f 30 - Prednison NA 
OA 1 95 f NA - - NA 
 2 70 f NA + - NA 
3 53 f NA + - NA 
 4 61 f NA - - NA 
 5 71 m NA - - NA 
 6 73 f NA - - NA 
 7 70 m NA - - NA 
 8 82 f NA - - NA 
 9 62 m NA - - NA 
 10 79 m NA - - NA 
 11 72 f NA - - NA 
 
RA: rheumatoid arthritis; OA: osteoarthritis; f/m: female/male; NSAIDs: non-steroidal anti-
inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs; RF pos: rheumatoid 
factor positivity; MTX: methotrexate ; NA : not assessed. 
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